2. Cell Cycle/DNA Damage Apoptosis Immunology/Inflammation
  3. Topoisomerase Caspase Apoptosis SOD
  4. Quercetin-3'-O-glucoside

Quercetin-3'-O-glucoside is an orally active flavonoid glycoside. Quercetin-3'-O-glucoside reduces liver glucose-6-phosphatase activity, alters serum insulin and glucose levels, and regulates the activities of antioxidant enzymes in the liver and kidney. Quercetin-3'-O-glucoside inhibits DNA topoisomerase II, induces S-phase cell cycle arrest and caspase-3-mediated apoptosis in hepatocellular carcinoma cells. Quercetin-3'-O-glucoside selectively inhibits EGFR-mediated signaling pathways targeting AKT, ERK1/2, FAK and MEK1/2. Quercetin-3'-O-glucoside inhibits growth factor-induced migration and invasion in pancreatic cancer cells. Quercetin-3'-O-glucoside exerts free radical scavenging effects. Quercetin-3'-O-glucoside is applicable to research related to pancreatic cancer, diabetes, hepatocellular carcinoma and malignant tumors.

For research use only. We do not sell to patients.

Quercetin-3'-O-glucoside

Quercetin-3'-O-glucoside Chemical Structure

CAS No. : 19254-30-9

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Quercetin-3'-O-glucoside Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Quercetin-3'-O-glucoside

View All Topoisomerase Isoform Specific Products:

View All Isoforms
Topoisomerase Topo I Topo II DNA gyrase

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Quercetin-3'-O-glucoside is an orally active flavonoid glycoside. Quercetin-3'-O-glucoside reduces liver glucose-6-phosphatase activity, alters serum insulin and glucose levels, and regulates the activities of antioxidant enzymes in the liver and kidney. Quercetin-3'-O-glucoside inhibits DNA topoisomerase II, induces S-phase cell cycle arrest and caspase-3-mediated apoptosis in hepatocellular carcinoma cells. Quercetin-3'-O-glucoside selectively inhibits EGFR-mediated signaling pathways targeting AKT, ERK1/2, FAK and MEK1/2. Quercetin-3'-O-glucoside inhibits growth factor-induced migration and invasion in pancreatic cancer cells. Quercetin-3'-O-glucoside exerts free radical scavenging effects. Quercetin-3'-O-glucoside is applicable to research related to pancreatic cancer, diabetes, hepatocellular carcinoma and malignant tumors[1][2][3][4][5][6].

IC50 & Target[1]

Caspase 3

 

In Vitro

Quercetin-3-O-glucoside (1-1000 nM; 72 h) exhibits no significant cytotoxicity toward CFPAC-1, Panc-1, SNU-213 human pancreatic cancer cells, or HUVEC normal cells following 72 h of treatment at concentrations up to 1000 nM[1].
Quercetin-3-O-glucoside (50-1000 nM; 6 h) dose-dependently inhibits EGF-induced migration of SNU-213 (up to 45% reduction) and CFPAC-1 (up to 30% reduction) human pancreatic cancer cells after 6 h of treatment, with no effect on PDGF-induced migration or basal migration of HUVEC normal cells[1].
Quercetin-3-O-glucoside (10-100 nM; 1 h pre-incubation, 10 min EGF stimulation) dose-dependently inhibits EGF-induced activation of the EGFR-mediated FAK, AKT, MEK1/2, and ERK1/2 signaling pathway in SNU-213 and CFPAC-1 human pancreatic cancer cells following 1 h pre-incubation and 10 min EGF stimulation[1].
Quercetin-3'-O-glucoside (1, 10, 50, 100, 150, 200 μM; 24, 48, 72 h) inhibits the growth of HepG2 cells in a dose- and time-dependent manner, with 200 μM inducing 50% inhibition at 24 h and 50, 100 μM inducing up to 98% inhibition at 48 and 72 h[3].
Quercetin-3'-O-glucoside (100 μM; 6, 12, 18, 24, 48 h) reduces HepG2 cell membrane integrity in a time-dependent manner, causing 93% cell damage after 48 h of incubation[3].
Quercetin-3'-O-glucoside (100 μM; 24 h) blocks HepG2 cell cycle progression in the S phase after 24 h of incubation, hindering DNA synthesis[3].
Quercetin-3'-O-glucoside (100 μM; 24, 48, 72 h) induces severe morphological changes, including apoptotic body formation, in HepG2 cells after 48 and 72 h of incubation, with changes also observed after 24 h[3].
Quercetin-3'-O-glucoside (100 μM; 24, 48 h) activates caspase-3 in HepG2 cells in vitro in a time-dependent manner, with greater activity observed after 48 h of incubation compared to 24 h[3].
Quercetin-3'-O-glucoside (100-1000 mg/mL; 16 h) exhibits low cytotoxicity to McCoy cells, with an IC50 of 215.2 mg/mL[4].
Quercetin-3'-O-glucoside (100-500 μg/mL; 1 week) exhibits high phytotoxicity against Lactuca sativa L. CV. Varamin seeds, with an IC50 of 282.78 μg/mL for germination inhibition[4].
Quercetin-3'-O-glucoside (100 mg/mL; 24 h (bacteria), 48 h (yeast)) has no antibacterial or antifungal activity against tested bacterial and yeast strains[4].
Quercetin-3'-O-glucoside (50-100000 nM) inhibits growth factor-induced migration in SNU-213 human pancreatic adenocarcinoma cells, with dose-dependent activity against bFGF-induced migration[6].
Quercetin-3'-O-glucoside (100-500 nM; 1 h pre-treatment; combined with gemcitabine) inhibits bFGF-induced activation of the FAK and ERK1/2 signaling pathways in SNU-213 human pancreatic adenocarcinoma cells[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Quercetin-3'-O-glucoside Related Antibodies

Western Blot Analysis[1]

Cell Line: SNU-213, CFPAC-1 human pancreatic cancer cells
Concentration: 10 nM, 50 nM, 100 nM
Incubation Time: 1 h pre-incubation; 10 min EGF-stimulation
Result: Dose-dependently inhibited EGF-induced phosphorylation of EGFR (Tyr1068), FAK (Tyr397), AKT (Ser473), MEK1/2 (Ser217/221), and ERK1/2 (Thr202/Tyr204) in both SNU-213 and CFPAC-1 cells.

Cell Proliferation Assay[3]

Cell Line: Human hepatocellular carcinoma HepG2 cells
Concentration: 1, 10, 50, 100, 150, 200 μM
Incubation Time: 24 h; 48 h; 72 h
Result: Induced dose- and time-dependent cell growth inhibition.
Induced 50% cell growth inhibition at 200 μM after 24 h.
Induced up to 98% cell growth inhibition at 50 and 100 μM after 48 and 72 h.

Cell Cycle Analysis[3]

Cell Line: human hepatocellular carcinoma HepG2 cells
Concentration: 100 μM
Incubation Time: 24 h
Result: Significantly increased the population of cells in the S phase.
Decreased the G1/G0 phase population compared to controls.

Apoptosis Analysis[3]

Cell Line: human hepatocellular carcinoma HepG2 cells
Concentration: 100 μM
Incubation Time: 24, 48, 72 h
Result: Induced apoptosis in treated cells, with most cells showing annexin V-only (green) staining (apoptotic cells).
Resulted in fewer cells showing annexin V and propidium iodide (yellow) staining (late apoptotic cells) or propidium iodide-only (red) staining (necrotic cells).
In Vivo

Quercetin-3'-O-glucoside (15 mg/kg; p.o.; daily; 10 consecutive days) elicits potent antidiabetic and antioxidative effects in Alloxan (HY-W017227)-induced diabetic Wistar rats, while normalizing oxidative stress markers in liver and kidney tissues[2].
Quercetin-3-O-glucoside (10-200 μM; incorporated into NGM culture medium; continuous exposure from L1 larval stage) extends the mean lifespan of wild-type Caenorhabditis elegans by up to 23% at doses of 10 μM and 25 μM, while reducing mean lifespan by 17% at a dose of 200 μM[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar (male, 9 weeks old, 160 ± 10 g, Alloxan-induced diabetes)[2]
Dosage: 15 mg/kg
Administration: p.o.; daily; 10 consecutive days
Result: Increased body weight by +4.78% relative to Alloxan-treated diabetic rats.
Reduced water intake by -10.68% and food consumption by -7.62% relative to alloxan-treated diabetic rats.
Decreased serum glucose concentration by 63.97% and increased serum insulin concentration by 113.26% relative to diabetic controls.
Inhibited hepatic glucose-6-phosphatase activity.
Reduced renal lipid peroxidation (LPO), Increased renal superoxide dismutase (SOD) activity, renal catalase (CAT) activity, and renal glutathione (GSH) content.
Molecular Weight

464.38

Formula

C21H20O12
CAS No.
Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C1C2=C(O)C=C(O)C=C2OC(C3=CC(O[C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4O)O)O)CO)=C(C=C3)O)=C1O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (215.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1534 mL 10.7670 mL 21.5341 mL
5 mM 0.4307 mL 2.1534 mL 4.3068 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 98.48%

SDS (251 KB)

COA (251 KB) HNMR (116 KB) LCMS (94 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1534 mL 10.7670 mL 21.5341 mL 53.8352 mL
5 mM 0.4307 mL 2.1534 mL 4.3068 mL 10.7670 mL
10 mM 0.2153 mL 1.0767 mL 2.1534 mL 5.3835 mL
15 mM 0.1436 mL 0.7178 mL 1.4356 mL 3.5890 mL
20 mM 0.1077 mL 0.5384 mL 1.0767 mL 2.6918 mL
25 mM 0.0861 mL 0.4307 mL 0.8614 mL 2.1534 mL
30 mM 0.0718 mL 0.3589 mL 0.7178 mL 1.7945 mL
40 mM 0.0538 mL 0.2692 mL 0.5384 mL 1.3459 mL
50 mM 0.0431 mL 0.2153 mL 0.4307 mL 1.0767 mL
60 mM 0.0359 mL 0.1795 mL 0.3589 mL 0.8973 mL
80 mM 0.0269 mL 0.1346 mL 0.2692 mL 0.6729 mL
100 mM 0.0215 mL 0.1077 mL 0.2153 mL 0.5384 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Quercetin-3'-O-glucoside Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Quercetin-3'-O-glucoside19254-30-9TopoisomeraseCaspaseApoptosisSODSuperoxide DismutaseHepG2 cellsFAKhepatocellular carcinoma cellsAKTERK1/2Caenorhabditis eleganspancreatic cancer cellsWistar ratsMEK1/2EGFRInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Quercetin-3'-O-glucoside
Cat. No.:
HY-N12445
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.